ArticleClinical chemistry2005
Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome.
Article in Clinical chemistry, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Prognostic accuracy of MALDI-TOF mass spectrometric analysis of plasma in COVID-19.Life science alliance · 2021Article
- SARS-CoV-2-Encoded Proteome and Human Genetics: From Interaction-Based to Ribosomal Biology Impact on Disease and Risk Processes.Journal of proteome research · 2020Review
- SELDI-TOF-MS proteomic profiling of serum, urine, and amniotic fluid in neural tube defects.PloS one · 2014Article
- Advances in MALDI mass spectrometry in clinical diagnostic applications.Topics in current chemistry · 2014Review
- Mass spectrometry based proteomic studies on viruses and hosts--a review.Analytica chimica acta · 2011Review
- Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis.Clinical proteomics · 2010Article
- Using simple artificial intelligence methods for predicting amyloidogenesis in antibodies.BMC bioinformatics · 2010Article
- Serum protein signature may improve detection of ductal carcinoma in situ of the breast.Oncogene · 2010Article
- Application of proteomics methods for pathogen discovery.Journal of virological methods · 2010Article
- Review
- Construction of a multiplex allele-specific PCR-based universal array (ASPUA) and its application to hearing loss screening.Human mutation · 2008Article
- Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry.Journal of chromatography. A · 2007Review
- Human body fluid proteome analysis.Proteomics · 2006Review
- Serum amyloid A is not useful in the diagnosis of severe acute respiratory syndrome.Clinical chemistry · 2006Article
- Clinical proteomics: present and future prospects.The Clinical biochemist. Reviews · 2006Article
- Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome.Clinical chemistry · 2006Article
- Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).Perspectives in medical virology · 2006Review
- Proteomics for biodefense applications: progress and opportunities.Expert review of proteomics · 2005Review
- Proteomics and severe acute respiratory syndrome (SARS): emerging technology meets emerging pathogen.Clinical chemistry · 2005Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDefinitive early-stage diagnosis of severe acute respiratory syndrome (SARS) is important despite the number of laboratory tests that have been developed to complement clinical features and epidemiologic data in case definition. Pathologic changes in response to viral infection might be reflected in proteomic patterns in sera of SARS patients.
methodsWe developed a mass spectrometric decision tree classification algorithm using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Serum samples were grouped into acute SARS (n = 74; <7 days after onset of fever) and non-SARS [n = 1067; fever and influenza A (n = 203), pneumonia (n = 176); lung cancer (n = 29); and healthy controls (n = 659)] cohorts. Diluted samples were applied to WCX-2 ProteinChip arrays (Ciphergen), and the bound proteins were assessed on a ProteinChip Reader (Model PBS II). Bioinformatic calculations were performed with Biomarker Wizard software 3.1.1 (Ciphergen).
resultsThe discriminatory classifier with a panel of four biomarkers determined in the training set could precisely detect 36 of 37 (sensitivity, 97.3%) acute SARS and 987 of 993 (specificity, 99.4%) non-SARS samples. More importantly, this classifier accurately distinguished acute SARS from fever and influenza with 100% specificity (187 of 187).
conclusionsThis method is suitable for preliminary assessment of SARS and could potentially serve as a useful tool for early diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.